TSS
CNSP icon

Two Sigma Securities’s CNS Pharmaceuticals CNSP Stock Holding History

Two Sigma Securities’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,303
Closed -$12.9K – 1480
2025
Q2 		$12.9K Buy
+1,303
New +$16.3K ﹤0.01% 1284
2024
Q2 		– Sell
-1
Closed -$7.89K – 3064
2024
Q1 		$7.89K Buy
+1
New +$14.5K ﹤0.01% 2793
2022
Q4 		– Hold
0
– -$16K – 2668
2022
Q3 		– Hold
0
– – – 2324
2021
Q3 		– Hold
0
– -$22K – 1605
2021
Q2 		– Hold
0
– – – 1445

Other funds holding CNSP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Two Sigma Securities's CNSP Position: Q3 2025 in Review

Two Sigma Securities sold out of CNS Pharmaceuticals (CNSP) in Q3 2025, closing a stake of 1,303 shares — an estimated $12.9K sold.

Two Sigma Securities first reported a position in CNSP in Q1 2024 and held it in 2 quarters. The position peaked at $12.9K in Q2 2025. 8 funds tracked by Wall St. Rank hold CNSP as of Q3 2025.

  • Two Sigma Securities reported no remaining CNS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 1,303 CNS Pharmaceuticals shares in Q3 2025, an estimated $12.9K.
  • Two Sigma Securities first reported a position in CNS Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Two Sigma Securities's CNS Pharmaceuticals position peaked at $12.9K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.